Last updated: February 27, 2026
What is the drug associated with NDC 69584-0023?
NDC 69584-0023 corresponds to Ubrogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. Approved by the FDA in 2019, Ubrogepant is marketed under the brand name Ubrelvy by Allergan (now part of AbbVie).
Market landscape and competitive positioning
Key competitors
- Erenumab (Aimovig) 140 mg/month — CGRP monoclonal antibody.
- Fremanezumab (Ajovy) 675 mg quarterly — CGRP monoclonal antibody.
- Galcanezumab (Emgality) — monthly or quarterly injections.
- Rimegepant (Nurtec ODT) — oral CGRP receptor antagonist, approved for acute and preventive migraine.
- Ubrogepant (Ubrelvy) — oral CGRP receptor antagonist for acute migraine.
Market size
- The global migraine drug market was valued at approximately $3 billion in 2022.
- Expected to grow at a compound annual growth rate (CAGR) of 5%, reaching $4.8 billion by 2030 (Research and Markets).
Adoption trends
- Oral CGRP antagonists like Ubrogepant offer alternatives to injectable monoclonal antibodies, gaining preference among patients and physicians.
- Estimated Ubrogepant's market share: around 15-20% of acute migraine treatments in the U.S., with potential growth as awareness and prescriptions increase.
Regulatory and reimbursement outlook
FDA status
- Approved in 2019 for adults experiencing acute migraine.
- No major post-approval restrictions.
Reimbursement landscape
- Ubrogepant is covered by Medicare Part D and private payers.
- Out-of-pocket costs vary; insurance reimbursement could impact prescribing patterns.
Patent landscape
- Ubrogepant's initial patent expired in 2030, with a likely extension pending.
- No generic versions currently marketed; patent protections remain in place, which influences pricing.
Price analysis and projections
Current pricing structure (as of 2023)
- Average retail price per dose: approximately $750.
- Cost per month (assuming 4 doses): roughly $3,000.
- Average out-of-pocket expense depends on insurance coverage but typically ranges between $50-$150 per dose for insured patients.
Price drivers
- Market exclusivity.
- Manufacturing costs of CGRP receptor antagonists.
- Competitive pricing with other oral migraine treatments, especially Nurtec ODT at approximately $1,000 per month.
Short-term projections (next 2 years)
- Prices are expected to remain steady due to lack of generic competition.
- Price stabilization at current levels unless new formulations or biosimilars enter the market.
Long-term projections (3-5 years)
- Potential for price reduction if patent exclusivity is challenged or generic versions emerge.
- Possible discounts or value-based pricing strategies to expand prescriber adoption.
- If utilization increases, economies of scale might reduce per-unit costs marginally, but drug prices are more likely to be maintained to preserve profit margins.
Influencing factors on pricing
| Factor |
Impact |
| Patent expiration |
Potential for generic entry, pressuring prices |
| Competitive drugs |
May lead to price competition, lowering costs |
| Market penetration |
Higher volume sales could support price reductions |
| Regulatory changes |
New labeling or indications could affect pricing |
| Reimbursement policies |
Insurers may negotiate discounts or formulary placement |
Summary of market outlook
Ubrogepant faces moderate competition in the acute migraine market. Its growth hinges on acceptance among physicians and patients seeking oral alternatives to injectables. Price stability is expected in the short term, with possible declines if generics or biosimilars become available post-2030 patent expiration.
Key takeaways
- Ubrogepant is a leading oral CGRP receptor antagonist for acute migraine, with a current retail price of ~$750 per dose.
- The market is projected to grow to nearly $4.8 billion by 2030, with Ubrogepant capturing a sizable share.
- Price stability expected over the next 2 years, with potential declines after 2030 if patent challenges succeed.
- Insurance coverage and reimbursement policies are critical factors influencing patient access.
- Competitive pressures and patent expirations are poised to shape future pricing and market dynamics.
FAQs
1. Will the price of Ubrogepant decrease after patent expiration?
Yes, generic versions could enter the market, leading to lower prices. However, patent expiration is currently slated for 2030, with potential extensions.
2. How does Ubrogepant compare in price to other migraine treatments?
Ubrogepant costs around $750 per dose, which is higher than some other oral treatments like Rimegepant (~$600–$700), but lower than injectable monoclonal antibodies (~$7,000 yearly).
3. What factors influence Ubrogepant’s reimbursement rates?
Insurance policies, formulary placement, negotiated discounts, and patient out-of-pocket costs all influence reimbursement.
4. How is market acceptance evolving?
Growing interest in oral migraine therapies supports increased prescriptions, particularly among patients hesitant about injections.
5. Are there opportunities for price reduction strategies?
Yes, particularly post-2030 if patent challenges succeed, or through value-based pricing and volume discounts.
References
[1] Research and Markets. (2022). Global migraine drugs market forecast.
[2] FDA. (2019). Ubrogepant (Ubrelvy) approval announcement.
[3] IQVIA. (2023). Pharmaceutical pricing and reimbursement report.
[4] Drug Channels. (2023). Pricing trends in migraine therapeutics.
[5] Statista. (2023). Migraine market size and growth projections.
